Opinion
Survival World on MSNOpinion

Short barrel ARs turn heads fast, but do these 7.5-inch builds make sense beyond novelty?

Image Credit: Survival World ...
FiercePharma

In launching epinephrine nasal spray, ARS Pharma has a 'blue sky opportunity,' analyst says

Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals. But after the recent approval of neffy, the San Diego drugmaker is poised for an ...
Nasdaq

ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season

ARS Pharmaceuticals has announced a new agreement with ALK-Abelló A/S to co-promote neffy® (epinephrine nasal spray), an important treatment for severe allergic reactions, to almost 9,000 ...
Seeking Alpha

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics ...
Seeking Alpha

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's ...